Influence of liver disease and environmental factors on hepatic monooxygenase activity in vitro

  • M. J. Brodie
  • A. R. Boobis
  • C. J. Bulpitt
  • D. S. Davies
Originals
Received:
Accepted:

Summary

The effects of liver disease and environmental factors on hepatic microsomal cytochrome P-450 content, NADPH-cytochrome c reductase (reductase) activity and aryl hydrocarbon hydroxylase (AHH) activity have been simultaneously investigated in 70 patients undergoing diagnostic liver biopsy. The activity of reductase was not significantly affected by the presence of liver disease or any of the environmental factors studied. Cytochrome P-450 content decreased with increasing severity of liver disease whereas AHH activity was only significantly reduced in biopsies showing hepatocellular destruction. None of the parameters of monooxygenase activity varied significantly with the age or sex of the patients. Alcohol excess was associated with decreased cytochrome P-450 content and AHH activity and this effect was independent of the histological status of the biopsy. Both high caffeine intake and cigarette smoking increased AHH activity in the absence of any change in cytochrome P-450 content. There was a positive correlation between the number of meat meals eaten per week and cytochrome P-450 content. Chronic treatment with enzyme-inducing anticonvulsants appeared to increase both cytochrome P-450 content and AHH activity. Despite differential effects of liver disease and environmental influences on cytochrome P-450 content and AHH activity there was a highly significant correlation between the two parameters. The results of the present study correlate well with the known effects of disease and environment on drug metabolism in vivo.

Key words

liver disease environmental factors cytochrome P-450 NADPH-cytochrome c reductase aryl hydrocarbon hydroxylase caffeine alcohol cigarette smoking meat consumption 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Atlas SA, Vessel ES, Nebert DW (1976) Genetic control of interindividual variations in the inducibility of aryl hydrocarbon hydroxylase in cultured human lymphocytes. Cancer Res 36: 4619–4630PubMedGoogle Scholar
  2. 2.
    Black M, Perrett RD, Carter AE (1973) Hepatic bilirubin UDP-glucuronyl transferase activity and cytochrome P-450 content in a surgical population, and the effects of pre-operative drug therapy. J Lab Clin Med 81: 704–712PubMedGoogle Scholar
  3. 3.
    Bolt HM, Kappus H, Bolt M (1973) Effect of rifampicin treatment on the metabolism of oestradiol and 17-α-ethinyloestradiol by human liver microsomes. Eur J Clin Pharmacol 8: 301–307CrossRefGoogle Scholar
  4. 4.
    Boobis AR, Brodie MJ, Kahn GC, Fletcher DR, Saunders JH, Davies DS (1980) Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens. Br J Clin Pharmacol 9: 11–19PubMedGoogle Scholar
  5. 5.
    Brodie MJ, Boobis AR, Toverud E-L. Ellis W, Murray S, Dollery CT, Webster J, Harrison R (1980) Drug metabolism in white vegetarians. Br J Clin Pharmacol 9: 523–525PubMedGoogle Scholar
  6. 6.
    Darby FJ, Grundy RK (1973) The metabolism of ureyl-14C tolbutamide in vitro and in vivo in man. Life Sci 13: 97–105PubMedCrossRefGoogle Scholar
  7. 7.
    Davies DS, Thorgeirsson SS (1971) Mechanism of hepatic drug oxidation and its relationship to individual differences in rates of drug oxidation in man. Ann NY Acad Sci 179: 411–420PubMedGoogle Scholar
  8. 8.
    Dollery CT, Fraser HS, Mucklow JC, Bulpitt CJ (1979) Contribution of environmental factors to variability in human drug metabolism. Drug Metab Rev 9: 206–220Google Scholar
  9. 9.
    Farrell GC, Cooksley WGE, Powell LW (1979) Drug metabolism in liver disease: activity of hepatic microsomal metabolising enzymes. Clin Pharmacol Ther 26: 483–492PubMedGoogle Scholar
  10. 10.
    Fraser HS, Mucklow JC, Bulpitt CJ, Kahn C, Mould G, Dollery CT (1978) Environmental effects on antipyrine half-life. Clin Pharmacol Ther 22: 799–805Google Scholar
  11. 11.
    Fraser HS, Williams FM, Davies DL, Draffan GH, Davies DS (1976) Amylobarbitone hydroxylation kinetics in small samples of rat and human liver. Xenobiotica 6: 465–472PubMedCrossRefGoogle Scholar
  12. 12.
    Hoensch H, Hartmann F, Schomerus H, Bieck P, Dolle W (1979) Monooxygenase enzyme activity in alcoholics with varying degrees of liver damage. Gut 20: 666–672PubMedGoogle Scholar
  13. 13.
    Homeida M, Karrar ZA, Roberts CJC (1979) Drug metabolism in malnourished children: a study with antipyrine. Arch Dis Child 54: 299–302PubMedCrossRefGoogle Scholar
  14. 14.
    Hunt SN, Jusko WJ, Yurchak AM (1976) Effect of smoking on theophylline disposition. Clin Pharmacol Ther 19: 546–551PubMedGoogle Scholar
  15. 15.
    Kalamegham R, Krishnaswamy K, Krishnamurthy S, Bhargava RNK (1979) Metabolism of drugs and carcinogens in man: antipyrine elimination as an indicator. Clin Pharmacol Ther 25: 67–73PubMedGoogle Scholar
  16. 16.
    Kapitulnik J, Poppers PJ, Conney AH (1979) Comparative metabolism of benzo(a)pyrene and drugs in human liver. Clin Pharmacol Ther 21: 166–176Google Scholar
  17. 17.
    Kappas A, Anderson KE, Conney AH, Alvares AP (1976) Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clin Pharmacol Ther 20: 643–653PubMedGoogle Scholar
  18. 18.
    Kratz E (1976) Coumarin-7-hydroxylase activity in microsomes from needle biopsies of normal and diseased human liver. Eur J Clin Pharmacol 10: 133–137PubMedCrossRefGoogle Scholar
  19. 19.
    Kuntzman R, Pantuck EJ, Kaplan SA, Conney AH (1977) Phenacetin metabolism: effect of hydrocarbons and cigarette smoking. Clin Pharmacol Ther 22: 757–764PubMedGoogle Scholar
  20. 20.
    Lieber CS (1973) Liver adaptation and injury in alcoholism. N Engl J Med 288: 356–362PubMedCrossRefGoogle Scholar
  21. 21.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275PubMedGoogle Scholar
  22. 22.
    Matsubara T, Baron J, Peterson LL, Peterson JA (1976) NADPH-cytochrome P-450 reductase. Arch Biochem Biophys 172: 463–469PubMedCrossRefGoogle Scholar
  23. 23.
    Mazel P (1971) Experiments illustrating drug metabolism in vitro. In: La Du BN, Mandel HG, Way EL (eds) Fundamentals of drug metabolism and drug disposition. Williams and Wilkins, Baltimore, pp. 546–582Google Scholar
  24. 24.
    O'Malley K, Crooks J, Duke E, Stevenson IH (1971) The effect of age and sex on human drug metabolism. Br Med J 3: 607–609PubMedCrossRefGoogle Scholar
  25. 25.
    Omura T, Sato R (1964) The carbon monoxide-binding pigment of liver microsomes 1. Evidence for its haemoprotein nature. J Biol Chem 239: 2370–2378PubMedGoogle Scholar
  26. 26.
    Pelkonen O, Kaltiala EH, Karki NT, Jalonen K, Pyorala K (1975) Properties of benzpyrene hydroxylase from human liver and comparison with the rat, rabbit and guinea pig enzymes. Xenobiotica 5: 501–509PubMedCrossRefGoogle Scholar
  27. 27.
    Pelkonen O, Kaltiala EH, Larmi TKI, Karki NT (1973) Comparison of activities of drug-metabolising enzymes in human fetal and adult livers. Clin Pharmacol Ther 14: 840–846PubMedGoogle Scholar
  28. 28.
    Pirttiaho HI, Sotaniemi EA, Ahlqvist J, Pitkanen U, Pelkonen RO (1978) Liver size and indices of drug metabolism in alcoholics. Eur J Clin Pharmacol 13: 61–67PubMedCrossRefGoogle Scholar
  29. 29.
    Rubin E, Lieber CS (1968) Hepatic microsomal enzymes in man and rat: induction and inhibition by ethanol. Science 162: 690–691PubMedGoogle Scholar
  30. 30.
    Sato N, Kamada T, Abe H, Suematso T, Kawano S, Hayashi N, Matsumara T, Hagihara B (1977) Simultaneous measurement of mitochondrial and microsomal cytochrome levels in human liver biopsy. Clin Chim Acta 80: 243–251PubMedCrossRefGoogle Scholar
  31. 31.
    Schoene B, Fleischmann RA, Remmer H, Olderhausen HFV (1972) Determination of drug metabolising enzymes in needle biopsies of human liver. Eur J Clin Pharmacol 4: 65–73PubMedCrossRefGoogle Scholar
  32. 32.
    Sellers EM, Holloway MR (1978) Drug kinetics and alcohol ingestion. Clin Pharmacokinet 3: 440–452PubMedGoogle Scholar
  33. 33.
    Sotaniemi EA, Ahlqvist J, Pelkonen RO, Pirttiaho H, Luoma PV (1977) Histological changes in the liver and indices of drug metabolism in alcoholics. Eur J Clin Pharmacol 11: 295–303PubMedCrossRefGoogle Scholar
  34. 34.
    Sotaniemi EA, Anttila M, Pelkonen RO, Jarvensivu P, Sundquist H (1979) Plasma clearance of propranolol and sotalol and hepatic drug-metabolising enzyme activity. Clin Pharmacol Ther 26: 153–161PubMedGoogle Scholar
  35. 35.
    Sotaniemi EA, Pelkonen RO, Ahokas J, Pirttiaho HI, Ahlqvist J (1978) Drug metabolism in epileptics: in vivo and in vitro correlations. Br J Clin Pharmacol 5: 71–76PubMedGoogle Scholar
  36. 36.
    Vesell ES (1979) The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther 26: 275–286PubMedGoogle Scholar
  37. 37.
    Vestal RE, Norris AH, Tobin JD, Cohen BH, Shock NW, Andres R (1975) Antipyrine metabolism in man: influence of age, alcohol, caffeine and smoking. Clin Pharmacol Ther 18: 425–432PubMedGoogle Scholar
  38. 38.
    Wang IY, Rasmussen RE, Creasy R, Crocker TT (1977) Metabolites of benzo(a)pyrene produced by placental microsomes from cigarette smokers and non-smokers. Life Sci 20: 1265–1272PubMedCrossRefGoogle Scholar
  39. 39.
    Wilkinson GR, Schenker S (1975) Drug disposition and liver disease. Drug Metab Rev 4: 139–175PubMedGoogle Scholar
  40. 40.
    Wilmana PF, Brodie MJ, Mucklow JC, Fraser HS, Toverud E-L, Davies DS, Dollery CT, Hillyard CJ, MacIntyre I, Park B (1979) Reduction of circulating 25-hydroxyvitamin D by antipyrine. Br J Clin Pharmacol 8: 523–528PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • M. J. Brodie
    • 1
  • A. R. Boobis
    • 1
  • C. J. Bulpitt
    • 1
  • D. S. Davies
    • 1
  1. 1.Department of Clinical PharmacologyRoyal Postgraduate Medical SchoolLondonUK

Personalised recommendations